A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Trial details
- Registry ID
- NCT05271604
- Drugs studied
- Cetuximab, Evalstotug (BA3071), Ozuriftamab Vedotin, Pembrolizumab
TrialRedline tracks 2 clinical trials sponsored by BioAtla, Inc.: 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckNCT05271604 | Cetuximab, Evalstotug (BA3071), Ozuriftamab Vedotin, Pembrolizumab | Completed | 2025-09-22Actual |
| CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLCNCT04681131 | CAB-AXL-ADC, PD-1 inhibitor | Completed | 2025-07-09Actual |
Names as written in the registry records.